Transition Agreements in the Biotechnology Industry
112 Contracts & Agreements
- 2seventy bio, Inc. (2 contracts)
- AbbVie Inc. (2)
- ACADIA PHARMACEUTICALS INC (1)
- ADMA BIOLOGICS, INC. (2)
- Alector, Inc. (1)
- Allena Pharmaceuticals, Inc. (2)
- Alliqua BioMedical, Inc. (2)
- Allogene Therapeutics, Inc. (1)
- Allovir, Inc. (1)
- Altimmune, Inc. (1)
- Aptevo Therapeutics Inc. (3)
- Arcellx, Inc. (1)
- Arcutis Biotherapeutics, Inc. (1)
- Athenex, Inc. (1)
- BioAtla, Inc. (1)
- Biogen Inc. (1)
- BIOMARIN PHARMACEUTICAL INC (4)
- Biostage, Inc. (2)
- BIOTIME INC (2)
- bluebird bio, Inc. (3)
- CANCER GENETICS, INC (1)
- CATALYST BIOSCIENCES, INC. (2)
- CATALYST PHARMACEUTICALS, INC. (2)
- Celsion CORP (1)
- Constellation Alpha Capital Corp. (1)
- CONTRAFECT Corp (1)
- Cyclerion Therapeutics, Inc. (2)
- CytoDyn Inc. (1)
- Deciphera Pharmaceuticals, Inc. (1)
- Dermira, Inc. (1)
- Dicerna Pharmaceuticals Inc (2)
- EXACT SCIENCES CORP (1)
- FIBROGEN INC (1)
- Gain Therapeutics, Inc. (1)
- GERON CORP (2)
- GLYCOMIMETICS INC (1)
- Gossamer Bio, Inc. (1)
- Grail, Inc. (1)
- GTX INC (1)
- iBio, Inc. (1)
- IMMUNOMEDICS INC (1)
- Karyopharm Therapeutics Inc. (3)
- Mirum Pharmaceuticals, Inc. (1)
- Moderna, Inc. (1)
- NEWLINK GENETICS CORP (1)
- NTN BUZZTIME INC (1)
- Nuo Therapeutics, Inc. (2)
- OncoCyte Corp (1)
- OPGEN INC (1)
- PDL BIOPHARMA, INC. (2)
- Pfenex Inc. (2)
- Praxis Precision Medicines, Inc. (1)
- Progenics Pharmaceuticals, Inc. (2)
- PUMA BIOTECHNOLOGY, INC. (1)
- Radius Health, Inc. (2)
- Retrophin, Inc. (1)
- RIGEL PHARMACEUTICALS INC (1)
- Sana Biotechnology, Inc. (1)
- SELECTA BIOSCIENCES INC (3)
- Sierra Oncology, Inc. (1)
- SOLENO THERAPEUTICS INC (1)
- Spring Bank Pharmaceuticals, Inc. (1)
- SUNESIS PHARMACEUTICALS INC (2)
- Surface Oncology, Inc. (1)
- Talaris Therapeutics, Inc. (1)
- Tonix Pharmaceuticals Holding Corp. (1)
- Ultragenyx Pharmaceutical Inc. (3)
- Vaxart, Inc. (1)
- Vericel Corp (5)
- VICAL INC (2)
- Viela Bio, Inc. (1)
- Vigil Neuroscience, Inc. (1)
- VITAL THERAPIES INC (1)
- XBiotech Inc. (2)
- Xenetic Biosciences, Inc. (1)
- Amendment to Transition Services Agreement between Eisai Inc., a subsidiary of Eisai and the Company, dated as of July 31, 2023 (certain identified information has been excluded... (CATALYST PHARMACEUTICALS, INC., Filed With SEC on August 9, 2023)
- Amendments 1, 2 and 3 to License and Transition Services Agreement with Forma Therapeutics, Inc (RIGEL PHARMACEUTICALS INC, Filed With SEC on August 1, 2023)
- TRANSITION SERVICES AGREEMENT (Tonix Pharmaceuticals Holding Corp., Filed With SEC on July 3, 2023)
- Transition Agreement and Release by and between the Company and Sunil Agarwal, dated as of April 28, 2023 (Sana Biotechnology, Inc., Filed With SEC on May 8, 2023)
- Transition Agreement, by and between the Company and John Dobak, dated March 1, 2023 (Constellation Alpha Capital Corp., Filed With SEC on May 4, 2023)
- Transition Agreement dated February 21, 2023, by and between the Company and John Magnani, Ph.D (GLYCOMIMETICS INC, Filed With SEC on May 3, 2023)
- Transition and Release Agreement, by and between Fresh Tracks Therapeutics, Inc. and Robert B. Brown, dated as of February 1, 2023 (VICAL INC, Filed With SEC on February 7, 2023)
- Form of Transition Services Agreement between Eisai, Inc., a subsidiary of Eisai, and the Company (certain identified information has been excluded from the exhibit because it... (CATALYST PHARMACEUTICALS, INC., Filed With SEC on December 22, 2022)
- Transition Agreement, by and between the Registrant and Suzanne T. Ildstad, dated August 13, 2022 (Talaris Therapeutics, Inc., Filed With SEC on November 10, 2022)
- Transition Agreement, by and between the Company and Eric Richman, dated September 19, 2022 (Gain Therapeutics, Inc., Filed With SEC on September 20, 2022)
- Transition Agreement and Release, dated as of August 14, 2022, by and between Cara Cassino, M.D. and ContraFect Corporation (CONTRAFECT Corp, Filed With SEC on August 16, 2022)
- Amendment to the Transition Services Agreement, by and between 2seventy bio, Inc. and the Registrant (bluebird bio, Inc., Filed With SEC on August 4, 2022)
- Transition Agreement dated July 26, 2022, by and between Praxis Precision Medicines, Inc. and Bernard Ravina (Praxis Precision Medicines, Inc., Filed With SEC on July 26, 2022)
- Transition Services Agreement, dated as of (VICAL INC, Filed With SEC on May 3, 2022)
- Transition Agreement, dated March 28, 2022, between the Company and Sharon Shacham (Karyopharm Therapeutics Inc., Filed With SEC on March 29, 2022)
- Transition Agreement, dated March 28, 2022, between the Company and Michael G. Kauffman (Karyopharm Therapeutics Inc., Filed With SEC on March 29, 2022)
- Transition Agreement and Release dated March 22, 2022 between the Company and Mark Kowalski (Sierra Oncology, Inc., Filed With SEC on March 23, 2022)
- Transition Agreement and Release between the Registrant and David Hilbert, Ph.D., dated January 7, 2022 (Arcellx, Inc., Filed With SEC on January 14, 2022)
- Transition Agreement, by and between the Registrant and Richard A. Fisher, dated November 17, 2021 (Vigil Neuroscience, Inc., Filed With SEC on November 19, 2021)
- Amendment to Executive Transition Services Agreement (Aptevo Therapeutics Inc., Filed With SEC on November 12, 2021)
- Executive Transition Services Agreement (Aptevo Therapeutics Inc., Filed With SEC on November 12, 2021)
- Transition Agreement by and between FibroGen, Inc. and Pat Cotroneo, dated as of August 14, 2021 (FIBROGEN INC, Filed With SEC on November 9, 2021)
- Transition Services Agreement, dated as of November 3, 2021, by and between 2seventy bio, Inc. and bluebird bio, Inc (2seventy bio, Inc., Filed With SEC on November 4, 2021)
- Transition Services Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc (2seventy bio, Inc., Filed With SEC on November 4, 2021)
- Transition Services Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc (bluebird bio, Inc., Filed With SEC on November 4, 2021)
- Transition Services Agreement, dated as of November 3, 2021, by and between 2seventy bio, Inc. and bluebird bio, Inc (bluebird bio, Inc., Filed With SEC on November 4, 2021)
- Transition Agreement dated October (Retrophin, Inc., Filed With SEC on October 12, 2021)
- Transition Agreement, dated September 7, 2021, by and between Shehnaaz Suliman and Alector, LLC (Alector, Inc., Filed With SEC on September 7, 2021)
- Transition Agreement by and between AlloVir, Inc. and David Hallal, dated May 18, 2021 (Allovir, Inc., Filed With SEC on August 6, 2021)
- Transition Agreement by and between BioAtla, Inc. and Carolyn Anderson Short, dated March 23, 2021 (BioAtla, Inc., Filed With SEC on May 12, 2021)
- Employment Transition Agreement between Frank Hsu, M.D. and Registrant, dated February 24, 2021 (GTX INC, Filed With SEC on May 6, 2021)
- Transition Agreement, dated March 31, 2021, by and between Allena Pharmaceuticals, Inc. and Edward Wholihan (Allena Pharmaceuticals, Inc., Filed With SEC on April 2, 2021)
- Transition Agreement, dated November 17, 2020, by and between Sheila Gujrathi, M.D. and the Registrant (Gossamer Bio, Inc., Filed With SEC on February 26, 2021)
- Transition and CEO Support Agreement, dated February 9, 2020, by and between J. Jeffrey Goater and Surface Oncology, Inc (Surface Oncology, Inc., Filed With SEC on February 11, 2021)
- Amendment No. 2 dated October 8, 2020 to the Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc. dated as of March 5, 2020, as amended on August... (Ultragenyx Pharmaceutical Inc., Filed With SEC on October 13, 2020)
- Transition Services Agreement, dated as of September 30, 2020, between PDL BioPharma, Inc. and LENSAR, Inc (PDL BIOPHARMA, INC., Filed With SEC on October 2, 2020)
- Transition Agreement, dated as of September 25, 2020, between the Company and Christopher B. Primiano (Karyopharm Therapeutics Inc., Filed With SEC on September 25, 2020)
- Transition Agreement between the Company and Jeffrey T. Huber, dated October 12, 2017, as amended (Grail, Inc., Filed With SEC on September 9, 2020)
- Amendment dated as of August 28, 2020 to Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc. dated as of March 5, 2020 (Ultragenyx Pharmaceutical Inc., Filed With SEC on September 2, 2020)
- Transition Agreement and Release, dated June 25, 2020, between Selecta Biosciences, Inc. and Stephen Smolinski (SELECTA BIOSCIENCES INC, Filed With SEC on June 25, 2020)
